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BACKGROUND AND PURPOSE
Hypoxia in tumours is known to cause resistance to conventional chemotherapeutic drugs. In contrast, little is known about
the effects of hypoxia on targeted anti-cancer drugs. This study evaluated the effect of hypoxia on a series of clinically
approved tyrosine kinase inhibitors (TKIs).
EXPERIMENTAL APPROACH
The effect of hypoxia (0.1% oxygen) on the activity of conventional cytotoxic drugs (5-fluorouracil, doxorubicin and
vinblastine), the hypoxia-activated prodrug tirapazamine and 9 TKIs was determined in a panel of cell lines. Where hypoxia
had a marked effect on chemosensitivity, Western blot analysis was conducted to determine the effect of hypoxia on target
expression and the effect of TKIs on cell signalling response under aerobic and hypoxic conditions.
KEY RESULTS
Three patterns of chemosensitivity were observed: resistance under hypoxia, equitoxic activity against hypoxic and aerobic
cells, and preferential cytotoxicity to hypoxic cells. Significant hypoxia selectivity (independent of HIF1) was observed in the
case of dasatinib and this correlated with the ability of dasatinib to inhibit phosphorylation of Src at tyrosine 530. Sorafenib
was significantly less effective under hypoxic conditions but resistance did not correlate with hypoxia-induced changes in
Raf/MEK/ERK signalling.
CONCLUSIONS AND IMPLICATIONS
Hypoxia influences the activity of TKIs but in contrast to conventional cytotoxic drugs, preferential activity against hypoxic
cells can occur. The search for hypoxia-targeted therapies has been long and fruitless and this study suggests that some
clinically approved TKIs could preferentially target the hypoxic fraction of some tumour types.
Abbreviations
5FU, 5-fluorouracil; DMSO, dimethylsulphoxide; HCR, hypoxic cytotoxicity ratio; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide; TKI, tyrosine kinase inhibitor
Introduction
One of the characteristic features of solid tumours is the
development of a microenvironment caused by a poor and
inefficient vascular supply (Vaupel and Kelleher, 2013). This
physiological microenvironment is characterized by gradi-
ents of oxygen tension, nutrients, catabolites, cellular
metabolites, cell proliferation and extracellular pH, all of
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which vary as a function of distance from a supporting blood
vessel (Brown, 2002; Vaupel, 2010). The presence of hypoxia
has significant biological and therapeutic implications and
hypoxia is established as a marker of poor prognosis in many
cancer types (Vaupel, 2008). Resistance to conventional cyto-
toxic anti-cancer drugs has been extensively studied and
while it is widely acknowledged that resistance is caused by
hypoxia-induced reduction in cell proliferation, other
mechanisms are emerging (Brown, 2002; Rohwer and
Cramer, 2011; Brahimi-Horn et al., 2012; Flamant et al., 2012;
Onishi et al., 2012; Wu et al., 2012). In addition, the fact that
hypoxic cells reside some distance away from blood vessels
introduces drug delivery challenges and this further com-
pounds the resistance of this population of cells (Heldin et al.,
2004; Minchinton and Tannock, 2006). The need to develop
therapeutic approaches that target the hypoxic fraction was
recognized many years ago and seminal studies by Sartorelli’s
group showing that mitomycin C can target hypoxic cells
(Kennedy et al., 1980; Sartorelli et al., 1994) led to the search
for more effective hypoxia-selective drugs. Hypoxia-activated
bioreductive prodrugs were actively pursued for many years
and a number entered clinical trial (Wilson and Hay, 2011).
However, while elegant in concept, this approach has proved
extremely difficult to translate into clinical efficacy. Novel
compounds are still being developed (McKeage et al., 2011;
Weiss et al., 2011; Sun et al., 2012) and are in clinical trial, but
the fact remains that after 40 years of research and develop-
ment, no hypoxia-selective bioreductive drugs have been
approved for use in humans. The need to develop hypoxia-
selective drugs is even more important today as our under-
standing of the effect that hypoxia has on tumour biology
and therapy increases.
In contrast to conventional cytotoxic drugs, little or no
information has been published concerning the effects of
hypoxia on targeted therapeutics. Hypoxia is known to
induce a plethora of biochemical changes, many of which are
mediated by hypoxia-inducible factors (Rohwer and Cramer,
2011), and signal transduction pathways are influenced by
hypoxia. This is exemplified by studies demonstrating that
the expression of Src and phosphorylated Src proteins is
elevated in hypoxic regions of pancreatic and cervical carci-
noma xenografts (Pham et al., 2009). Furthermore, studies
using the Bcl-2 inhibitor ABT-737 clearly demonstrate that
targeted therapeutics can selectively kill hypoxic cells
(Harrison et al., 2011; Klymenko et al., 2011). The hypoxia-
selective activity of ABT-737 was attributed to hypoxia-
induced down-regulation of myeloid cell leukaemia
sequence-1, a protein that causes resistance to ABT-737
(Harrison et al., 2011). These studies demonstrate that
hypoxia can modulate the activity of targeted anti-cancer
drugs. The identification of clinically used tyrosine kinase
inhibitors (TKIs) that are selectively toxic to hypoxic cells
would be beneficial and would stimulate the design of novel
combination strategies with drugs that preferentially target
the aerobic fraction. In addition, resistance of hypoxic cells to
TKIs would significantly influence the outcome of chemo-
therapy and this knowledge could help tailor chemotherapy
to individuals who are most likely to benefit from these
drugs. Given the importance of TKIs and other small mol-
ecule drugs in treating cancer, it is imperative to characterize
the effects of hypoxia on the activity of targeted anti-cancer
drugs (Filippi et al., 2011). The aim of this study was to
determine whether the response of a panel of cell lines to
TKIs was influenced by hypoxia. Where differences between
cellular response under aerobic and hypoxic conditions were
obtained, additional studies were conducted to identify
mechanisms of action.
Methods
All standard cytotoxic drugs [doxorubicin, vinblastine and
5-fluorouracil (5FU)], tirapazamine and TKIs were prepared in
dimethylsulphoxide (DMSO), aliquoted and stored at −20°C
until required for use. All cell culture reagents were obtained
from Sigma Aldrich unless stated otherwise.
Cell lines and culture conditions
As little is known about the effects of hypoxia on TKIs, the
experimental design involved the evaluation of a number of
TKIs against a panel of human cancer cell lines. As the TKIs
evaluated had multiple mechanisms of action, it was not
feasible to select cell lines that harboured specific mutations
or activated pathways. In the initial phase of the project
therefore, the cell lines used were DLD-1 human colorectal
carcinoma, H460 and A549 human NSCLC cells, MDA-MB-
231 human breast cancer, and TK10 human renal cancer
cells. An extended panel of cell lines was used to study the
effects of hypoxia on the activity of dasatinib and these
consisted of MDA-MB- 468, MDA-MB-453, Hs578T, BT-20,
T47D and MCF7, all of which are derived from human breast
carcinomas. A549, H460, MDA-MB-231, MDA-MB-453, MCF7
and TK10 cells were obtained from the National Cancer Insti-
tute (Bethesda, MD, USA). DLD-1, Hs578T, BT20, T47D and
MDA-MB-468 cells were purchased from the American Type
Culture Collection (LGC Standards, London, UK).
Chemosensitivity studies
Chemosensitivity under aerobic and hypoxic conditions was
determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide) assay as described previously
(Phillips et al., 1992). Studies under hypoxia were performed
in a Whitley H35 Hypoxystation (Don Whitley Scientific,
Shipley, UK). In this study, hypoxia was defined as 0.1%
oxygen which is a physiologically relevant level of hypoxia
that is associated with resistance to radiotherapy, the induc-
tion of HIF1 activation and unfolded protein response
(Wilson and Hay, 2011). It is also important to stress that
these conditions are distinct from the majority of studies on
bioreductive prodrugs where conditions of anoxia are typi-
cally used to evaluate compounds (Wilson and Hay, 2011).
Initial validation of the MTT assay demonstrated that a linear
relationship between cell number and absorbance was
obtained under both hypoxic and aerobic conditions. Follow-
ing a 24 h exposure to 0.1% oxygen, linear regression analysis
of the relationship between cell number and absorbance was
identical to those obtained under aerobic conditions with the
exception of A549 cells where r values of 4.97 × 105 and 2.02
× 105 were obtained under aerobic and hypoxic conditions
respectively (data not shown). Even though the efficiency of
MTT conversion to formazan was reduced in A549 cells under
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hypoxia, the relationship between cell number and absorb-
ance is linear. To further confirm the suitability of the MTT
assay for use under hypoxic conditions, cellular response was
also determined by counting viable cells using a haemocy-
tometer following continuous exposure to dasatinib.
For chemosensitivity studies, cells were plated into
96-well plates at a density of 2 × 103 cells per well and
incubated under aerobic or hypoxic conditions (0.1%
oxygen) at 37°C in a CO2-enriched atmosphere overnight to
allow cells to attach. On the following day, media was
removed from each well and replaced with media containing
test compounds at a range of concentrations (8 wells per drug
concentration). For hypoxia studies, drugs were diluted in
media that had been conditioned under hypoxia for at least
24 h prior to the start of the experiment. Following a 5 days
incubation at 37°C in a CO2-enriched atmosphere, MTT
(0.5 mg·mL−1) was immediately added to each well and incu-
bated for 4 h. Formazan crystals were dissolved in DMSO and
the absorbance of the resulting solution was measured at
570 nm. Cell survival was determined as the true absorbance
of the treated wells divided by the controls and expressed as
a percentage. The effect of hypoxia on the activity of drugs
was expressed as the hypoxic cytotoxicity ratio (HCR), which
is defined as the ratio of IC50 values under aerobic to hypoxic
conditions.
Antibodies and Western blot analysis
Antibodies to Src and p-Src (Src antibody sampler kit), ErbB
(EGF) receptor and p-ErbB receptor signalling pathways
(Phosph-EGFR antibody sampler kit), Raf signalling (Raf
family antibody sampler kit) and phospo-ERK1/2 signalling
(phosphor-ERK1/2 pathway sampler kit) were obtained from
Cell Signalling Technology® (Beverly, MA, USA). Antibodies
to β-actin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Secondary antibodies were horserad-
ish peroxidase-linked anti-mouse or anti-rabbit. To determine
the effect of selected TKIs on cell signalling, cells were con-
ditioned to hypoxia (0.1% oxygen) and normoxia for 24 h
before drug exposure. Cells were exposed to a range of drug
concentrations for a further 24 h before cell lysis and analysis
by Western blotting. Images of immunoblots were digitally
captured on Molecular Imager FX and individual bands were
quantified using Quantity One software (Biorad, Hemel
Hempstead, UK).
Role of HIF1 in the hypoxia-selective activity
of dasatinib
HIF1α protein expression was determined by Western blot
analysis following the incubation of MDA-MB-231, MDA-MB-
468 and MCF7 cells in 0.1% oxygen for 24 h. Western blot
analysis was performed using a purified mouse anti-HIF1α
antibody obtained from BD Biosciences (Oxford, UK) and
band intensities from three independent experiments were
quantified using Quantity One software (Biorad). Under
aerobic conditions, MDA-MB-231, MDA-MB-468 and MCF7
cells were exposed to CoCl2 for 6 h (150 μM) or 24 h (100 μM)
and HIFα expression determined as above. Once HIF1α
expression had been confirmed, cells were exposed to dasat-
inib for 1 h in the presence or absence of CoCl2 and cell
survival determined using the MTT assay following a 5 days
recovery period at 37°C.
Quantification of apoptosis following
exposure of cells to dasatinib under aerobic
and hypoxic conditions
MCF7, MDA-MB-468 and MDA-MB-231 cells were exposed to
a range of dasatinib concentrations under aerobic and
hypoxic conditions for 24 h. Cells were harvested by trypsi-
nization and the percentage of cells undergoing apoptosis
was determined by flow cytometry following Anexin-V-
FLUOS staining (Roche, Penzberg, Germany) as described pre-
viously (Allison et al., 2009).
Analysis of data
Statistical analysis of the results was conducted using Stu-
dent’s t test.
Results
Chemosensitivity studies
The response of cell lines to standard classic anti-cancer drugs
(doxorubicin, 5-FU and vinblastine) and the hypoxia-
selective agent tirapazamine are presented in Table 1 and
HCR values are presented graphically in Figure 1. The classic
anti-cancer drugs tested were generally more active against
cells under aerobic conditions compared with hypoxic (0.1%
oxygen) conditions with some exceptions. In the case of
doxorubicin, activity against MDA-MB-231 cells was similar
under aerobic and hypoxic conditions (IC50 = 0.42 ± 0.01 and
0.46 ± 0.05 μM, respectively) and TK10 cells were marginally
more responsive under hypoxic conditions (IC50 = 0.34 ± 0.03
and 0.26 ± 0.05 μM respectively). H460 cells were also equally
sensitive to vinblastine under aerobic and hypoxic conditions
(IC50 = 1.23 ± 0.03 and 1.36 ± 0.10 μM respectively). The
magnitude of the effect of hypoxia on the cellular response to
each drug was cell line dependent (Figure 1). The hypoxia-
selective agent tirapazamine was preferentially active against
all cell lines under hypoxic conditions although HCR values
varied across the panel of cell lines (2.71–9.63 in MDA-MB-
231 and A549 cells, respectively, Figure 1). Exposure to 0.1%
oxygen induced a partial G1 arrest in the majority of cell lines
within 24–48 h (data not shown). These results are consistent
with reduced cell growth observed under hypoxia (data not
shown) and resistance to the conventional cytotoxic drugs
evaluated in this study.
The response of cell lines to TKIs under hypoxic and
aerobic conditions is reported in Table 1 and HCR values are
presented in Figure 2. Three patterns of response were
observed: resistance under hypoxia (HCR < 1), equipotent
activity under aerobic and hypoxic conditions (HCR ≈ 1), and
sensitivity under hypoxia (HCR > 1). With the exception of
sorafenib, which was more resistant under hypoxia, and
imatinib, which was equally active under aerobic and
hypoxic conditions against all five cell lines, considerable
heterogeneity in HCR values to individual drugs exists across
the panel of cell lines tested (Table 1, Figure 2). This is illus-
trated most prominently in the case of dasatinib. Comparing
the response of cells to dasatinib under aerobic and hypoxic
conditions, A549 cells are resistant to dasatinib under
hypoxic conditions (HCR = 0.007) whereas MDA-MB-231
BJP M Ahmadi et al.
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cells were significantly (P < 0.01) more sensitive under
hypoxia compared with oxygenated cells (HCR = 5.50).
Haemocytometer counts of control and dasatinib-treated
MDA-MB-231 cells gave a HCR of 6.49 providing further
verification that the MTT assay is appropriate for use under
these experimental conditions. Other examples where all
three patterns of response exist include erlotinib, sunitinib,
nilotinib and masatinib (Figure 2). In contrast to the conven-
tional drugs tested, gefitinib, vandetinib and imatinib gener-
ally have equipotent activity under hypoxic and aerobic
conditions (Table 1, Figure 2).
As dasatinib induced a significant increase in response
under hypoxia in the MDA-MB-231 breast cancer cell line
and c-Src is a potential target in breast cancer (Tryfonopoulos
et al., 2011), the effect of dasatinib against an extended panel
of breast cancer cell lines was determined. The results are
presented in Table 2. As in the MDA-MB-231 cell line, dasat-
inib was significantly (P < 0.01) more potent under hypoxia
against MDA-MB-468 and MCF7 cell lines with HCR values of
5.23 and 15.00 respectively. The response of MDA-MB-453
and Hs578T cells was similar under aerobic and hypoxic
conditions with HCR values of 1.38 and 0.91 respectively. In
contrast, T47D and BT20 cells were significantly (P < 0.01)
more resistant under hypoxic conditions with HCR values of
0.62 and 0.12 respectively (Table 2). Whereas basal levels of
apoptosis in MDA-MB-468 cells were similar under aerobic
and hypoxic conditions, dasatinib induced significantly
(P < 0.01) more apoptosis across a range of doses in hypoxic
cells (Figure 3). This would account for the increased potency
of dasatinib observed under hypoxia. Similar results were
obtained for MDA-MB-231 and MCF7 cells (data not
shown).
Table 1
Response of a panel of cell lines to conventional cytotoxic drugs, tirapazamine and targeted therapeutics under normoxic (N) and hypoxic
(H) conditions
Drug A549 H460 MDA MB231 DLD1 TK10
5FU (N) 2.28 ± 0.56 1.97 ± 1.27 14.61 ± 9.23 3.03 ± 0.59 41.35 ± 7.92
5FU (H) 15.13 ± 3.72++ 6.54 ± 1.13++ 39.17 ± 5.21++ 12.62 ± 3.02++ 72.99 ± 25.38+
Dox (N) 0.25 ± 0.04 0.023 ± 0.006 0.42 ± 0.01 0.074 ± 0.004 0.34 ± 0.03
Dox (H) 1.00 ± 0.14++ 0.066 ± 0.011+ 0.46 ± 0.05 0.43 ± 0.05++ 0.26 ± 0.05
Vinblastine (N) 0.72 ± 0.05 1.23 ± 0.03 0.55 ± 0.06 2.47 ± 0.79 2.40 ± 0.17
Vinblastine (H) 2.13 ± 0.69++ 1.36 ± 0.10 0.85 ± 0.10 5.28 ± 0.44+ 7.43 ± 1.43++
Tirapazamine(N) 23.13 ± 3.41 22.85 ± 1.12 7.84 ± 0.86 15.91 ± 1.23 19.69 ± 2.54
Tirapazamine(H) 2.40 ± 1.34++ 2.53 ± 0.92++ 2.89 ± 0.65++ 2.95 ± 1.68++ 3.38 ± 1.15++
Sunitinib (N) 4.82 ± 0.31 3.73 ± 2.00 8.17 ± 1.13 2.85 ± 0.73 8.02 ± 0.63
Sunitinib (H) 4.97 ± 0.42 2.54 ± 0.47 5.08 ± 0.49 0.50 ± 0.09++ 5.92 ± 0.62
Sorafenib (N) 2.74 ± 1.50 1.42 ± 0.13 0.51 ± 0.34 1.16 ± 0.53 0.25 ± 0.05
Sorafenib (H) 21.63 ± 6.12++ 5.49 ± 0.95++ 2.10 ± 1.38++ 2.90 ± 0.77+ 9.02 ± 3.05++
Gefitinib (N) 23.32 ± 3.62 14.90 ± 1.11 10.62 ± 0.82 10.46 ± 1.94 0.97 ± 0.27
Gefitinib (H) 16.69 ± 2.41 22.34 ± 2.12++ 11.85 ± 0.78 7.22 ± 1.81+ 9.10 ± 3.50++
Masatinib (N) 18.17 ± 0.51 12.47 ± 1.52 8.39 ± 2.02 16.33 ± 3.10 14.72 ± 3.65
Masatinib (H) 18.75 ± 2.81 18.47 ± 1.04++ 12.93 ± 2.23+ 5.34 ± 0.61++ 10.40 ± 0.78
Vandetinib (N) 7.60 ± 3.77 8.75 ± 0.78 8.12 ± 0.99 6.68 ± 1.90 2.35 ± 1.92
Vandetinib (H) 8.07 ± 0.84 10.54 ± 0.37 5.56 ± 2.56+ 4.25 ± 0.53+ 1.82 ± 0.39
Dasatinib (N) 0.17 ± 0.01 14.52 ± 1.48 33.0 ± 9.53* 2.25 ± 0.04 3.62 ± 1.08*
Dasatinib (H) 23.92 ± 8.58++ 11.18 ± 1.27 6.0 ± 4.35*++ 25.09 ± 4.43++ 12.17 ± 2.55*++
Nilotinib (N) 7.61 ± 0.86 5.86 ± 1.89 2.81 ± 1.00 8.08 ± 2.64 1.12 ± 0.68
Nilotinib (H) 9.98 ± 1.66 9.04 ± 0.94+ 1.73 ± 1.02 5.39 ± 0.42 24.53 ± 0.99++
Imatinib (N) 32.77 ± 0.85 23.76 ± 2.15 18.28 ± 0.68 21.58 ± 1.68 15.90 ± 3.17
Imatinib (H) 33.28 ± 3.85 22.89 ± 3.10 19.69 ± 1.30 17.54 ± 1.20 18.96 ± 1.71
Erlotinib (N) 3.74 ± 0.67 11.58 ± 0.85 15.70 ± 0.36 10.33 ± 0.65 4.71 ± 2.12
Erlotinib (H) 33.83 ± 3.23++ 29.58 ± 10.99++ 20.11 ± 0.54+ 7.56 ± 0.81+ 47.25 ± 8.41++
Cells were pre-incubated under normoxic and hypoxic (0.1% oxygen) conditions for 24 h before a 96 h exposure to each drug. Cell survival
was determined using the MTT assay and results are expressed as IC50 values. The units are μM in all cases with the exception of those marked
by an asterisk where the units are in nM. Each value represents the mean ± SD of three independent experiments. Statistical analysis
comparing response under hypoxia to aerobic conditions was performed using Student’s t-test and P-values of <0.05 and 0.01 are
represented as + and ++ respectively.
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Based on the results, three compounds were selected for
further studies designed to explore the mechanistic basis for
hypoxia sensitivity or resistance. These were dasatinib, erlo-
tinib and sorafenib.
Influence of hypoxia on the expression of Src
The effect of 24 h exposure to 0.1% oxygen on Src and p-Src
levels in the panel of cell lines tested is presented in
Figure 4A. Under normoxic conditions, Src protein expres-
sion ranged from high (A549 and H460) to comparatively low
(DLD-1, MDA-MB-231 and TK10). Exposure to hypoxia
increased levels of Src expression in DLD-1, MDA MB 231,
A549 and TK10 but had little effect of Src levels in H460 cells.
Levels of pSrcY419 were influenced by exposure to hypoxia
with increased expression observed in all cell lines except
H460 cells (Figure 4A). Expression of pSrcY530 decreased
under hypoxia in all cells with the exception of DLD-1 cells
where hypoxia had no obvious effect on pSrcY530 expression
(Figure 4A).
Influence of dasatinib on Src signalling under
aerobic and hypoxic conditions
The effect of dasatinib on Src and pSrc expression has been
determined in hypoxia-sensitive and resistant cells taken
from both the initial panel of cell lines evaluated (Figure 4B)
and the extended panel of breast cancer lines (Figure 5). In
the initial panel of cell lines, the effect of hypoxia on Src and
p-Src expression 24 h after treatment with a range of dasat-
inib concentrations in A549 (hypoxia-resistant) and MDA-
MB-231 (hypoxia-sensitive) cells is presented in Figure 4B.
Under aerobic conditions, expression of pSrcY419 is reduced
by dasatinib at doses as low as 5 nM (Figure 4B). There was no
significant difference in the inhibition of pSrcY419 under
hypoxia and aerobic conditions in either cell line (Figure 4B).
A similar pattern of response was observed in the breast
cancer panel of cells with no major differences in the ability
of dasatinib to inhibit pSrcY419 expression under aerobic and
hypoxic conditions (Figure 5).
In contrast, differences in the ability of dasatinib to
inhibit the expression of pSrcY530 between aerobic and
hypoxic cells were observed. In the hypoxia-resistant A549
Figure 1
HCRs for 5FU, doxorubicin, vinblastine and tirapazamine. The centre line represents a HCR of 1, which indicates that the response of cells under
aerobic and hypoxia is equal. A HCR value greater than 1 indicates sensitivity under hypoxia. HCR of less than 1 indicates resistance under hypoxia.
Each HCR is calculated from mean IC50 values obtained from three independent experiments (Table 1). Experimental error in the form of standard
deviations for IC50 values is presented in Table 1.
Table 2
Response of a panel of breast carcinoma cell lines exposed to dasat-
inib under aerobic and hypoxic conditions for 96 h
Cell line
Aerobic
IC50 (μM)
Hypoxic
IC50 (μM) HCR
MCF7 0.18 ± 0.11 0.012 ± 0.007++ 15.00
MDA-MB-231 0.033 ± 0.009 0.006 ± 0.004++ 5.50
MDA-MB-468 16.58 ± 2.47 3.17 ± 1.70++ 5.23
MDA-MB-453 8.27 ± 3.36 5.97 ± 1.45 1.38
Hs578T 0.044 ± 0.016 0.048 ± 0.013 0.91
T47D 10.45 ± 2.98 16.85 ± 2.53+ 0.62
BT20 1.14 ± 0.59 9.63 ± 4.06++ 0.12
Each value represents the mean ± SD of at least three independ-
ent experiments. Statistical analysis comparing response under
hypoxia to aerobic conditions was performed using Student’s
t-test and P-values of <0.05 and 0.01 are represented as + and ++
respectively.
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cells, pSrcY530 was effectively inhibited by dasatinib under
aerobic conditions but not under hypoxic conditions
(Figure 4B). In the hypoxia-sensitive MDA-MB-231 cells,
pSrcY530 expression was preferentially inhibited by dasatinib
under hypoxic conditions (Figure 4B). A similar pattern of
response was observed in the extended panel breast cancer
cell lines but the differential effects of dasatinib on pSrc530
expression were less extreme (Figure 5). These results suggest
that the effects of dasatinib on pSrcY530 expression have a
greater impact on cell response under hypoxic conditions
than dephosphorylation of pSrcY419.
Role of HIF1 in the hypoxia-selective activity
of dasatinib
The role of HIF1 in the hypoxic potentiation of dasatinib
activity was determined in MCF7, MDA-MB-231 and MDA-
MB-468 cells (Figure 6). HIF1α expression was undetectable
in all three cell lines under aerobic conditions. Following a
24 h exposure to 0.1% oxygen, a prominent increase in
HIF1α levels was observed in the MCF7 and MDA-MB-468 cell
lines whereas only a very minor increase in HIF1α was
observed in MDA-MB-231 cells (Figure 6A). Under aerobic
conditions, treatment of cells with either 150 or 100 μM
CoCl2 for 6 or 24 h, respectively, induced HIF1α in all three
cell lines (Figure 6A). As treatment of cells with 150 μM CoCl2
for 6 h induced HIF1α expression significantly in all cell lines,
these conditions were used to determine the effect of HIF1α
on cellular response to dasatinib. As illustrated in Figure 6B,
the response of cell lines to dasatinib in the presence of CoCl2
was reduced (MCF7) or equivalent (MDA-MB-231 and MDA-
Figure 2
Influence of hypoxia (0.1% oxygen) on the response of a panel of human cancer cells lines to tyrosine kinase inhibitors. Each HCR is calculated
from mean IC50 values obtained from three independent experiments (Table 1). Experimental error for IC50 values is presented in Table 1.
Figure 3
Induction of cell death following the treatment of MDA-MB-468 cells
with dasatinib. Cells were exposed to dasatinib under aerobic and
hypoxic (0.1% oxygen) conditions for 24 h before analysis of early
apoptotic cells (annexin V positive cells) and cells undergoing late
apoptosis/necrosis [annexin V and propidium iodide (PI) positive
cells]. Each value represents the mean ± SD for three independent
experiments.
BJPHypoxia and tyrosine kinase inhibitor activity
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MB-468) to the response of cells treated with dasatinib alone.
These results, together with the very modest induction of
HIF1α under hypoxic conditions in the MDA-MB-231 cells,
suggest that the hypoxia-selective activity of dasatinib is
independent of HIF1.
Influence of hypoxia and exposure to erlotinib
on the expression of ErbB receptors
Under aerobic conditions, the expression of ErbB receptor
protein expression was highest in TK10, MDA-MB-231 and
A549 cells (Figure 7A). Under hypoxic conditions, there was a
significant increase in ErbB receptor levels in A549, DLD-1
and H460, whereas hypoxia had little effect in MDA-MB-231
and TK10 cells (Figure 7A). The expression of phosphorylated
ErbB receptor (p-ErbB receptor Y1068) shows marked differ-
ences under hypoxia. In TK10 cells, p-ErbB receptor was
strongly expressed under both aerobic and hypoxic condi-
tions, whereas in DLD-1 and A549 cells, there was a signifi-
cant increase in p-ErbB receptor under hypoxic conditions
(Figure 7A). No differences in the expression of p-ErbB recep-
tor occurred between aerobic and hypoxic conditions in
MDA-MB-231 cells and p-ErbB receptor was barely detectable
in H460 cells under both aerobic and hypoxic conditions
(Figure 7A).
The effect of erlotinib on ErbB receptor and p-ErbB recep-
tor levels in TK10 (hypoxia resistant) and DLD-1 (marginally
hypoxia sensitive) is presented in Figure 7B. In the hypoxia-
resistant TK10 cell line, treatment with erlotinib for 24 h did
not affect the levels of ErbB receptors but caused a dose-
dependent reduction in levels of p-ErbB receptors under both
hypoxic and aerobic conditions (Figure 7B). Under aerobic
conditions, levels of p-ErbB receptors were undetectable in
cells treated with 60 μM erlotinib, whereas under hypoxic
conditions, p-ErbB receptors were still detectable at 100 μM
(Figure 7B). In DLD1 cells where the effects of hypoxia on the
activity of erlotinib were marginally in favour of hypoxia
selectivity (HCR = 1.36), no significant differences in the
Figure 4
Influence of hypoxia and dasatinib on Src and p-Src levels. The influence of a 24 h exposure to 0.1% oxygen on the levels of Src, pSrcY419 and
pSrcY530 in five cell lines is presented in panel (A). In panel (A), MDA refers to the MDA-MB-231 cell line. The effect of dasatinib (in aerobic and
hypoxic conditions) on Src, pSrcY419 and pSrcY530 in the hypoxia-sensitive MDA-MB-231 and hypoxia-resistant A549 cells is presented in panel
(B). In both cases, cells were exposed to dasatinib for 24 h before harvesting for immunoblotting. Graphs show the quantification (±SD) of Src,
pSrc Y419 and pSrc Y530 after normalization to β-actin for a minimum of n = 3 experiments.
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ability of erlotinib to inhibit p-ErbB receptors were observed,
despite the increased expression of ErbB receptors under
hypoxia (Figure 7B).
Relationship between cellular response to
sorafenib and inhibition of Raf/MEK/ERK
signalling pathways
Chemosensitivity studies demonstrated that sorafenib was
the only drug that was less effective under hypoxic condi-
tions across the panel of cell lines evaluated. HCR values
ranged from 0.40 to 0.027 in DLD-1 and TK10 cells respec-
tively (Figure 2). The influence of hypoxia on the expression
of Raf/MEK/ERK signalling pathways is presented in Figure 8.
Exposure to 0.1% oxygen for 24 h affects the expression of
p-cRaf, p-MEK1,2, p44/42 MAPK and p90RSK in a cell line-
dependent manner (Figure 8) but these changes do not cor-
relate with the emergence of resistance to sorafenib under
hypoxia.
Discussion
The resistance of hypoxic cells to the classic cytotoxic anti-
cancer drugs has been broadly attributed to hypoxia-induced
changes in the cell cycle but more recent studies have dem-
onstrated that other mechanisms exist (Brahimi-Horn et al.,
2012; Flamant et al., 2012; Onishi et al., 2012; Wu et al.,
2012). With the exception of doxorubicin that can be equally
or more effective against certain cell types under hypoxic
conditions (Teicher et al., 1981; Luk et al., 1990), the majority
Figure 5
Influence of hypoxia and dasatinib on Src and pSrc expression in a hypoxia-sensitive and resistant breast cancer cell lines. Western blot analysis
of Src, pSrcY419 and pSrcY530 following the treatment of hypoxia-sensitive (MDA-MB-468 and MCF7) and resistant (BT20) cells with dasatinib
for 24 h under aerobic and hypoxic conditions. Graphs show the quantification (±SD) of Src, pSrcY419 and pSrcY530 (key to shading of columns
same as Figure 4) after normalization to β-actin for a minimum of n = 3 experiments.
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of cell lines used were resistant to classic cytotoxic drugs
under hypoxic conditions (Figure 1, Table 1). In contrast, the
response of cells to TKIs under aerobic and hypoxic condi-
tions varied in a cell line-dependent manner with three main
patterns of response observed (Table 1, Figure 2). These were
resistance under hypoxia, equitoxic effects under aerobic and
hypoxic conditions, and sensitivity under hypoxia. With the
exception of sorafenib (which was resistant under hypoxia in
all cell lines tested) and imatinib (which was equally active
against hypoxic and aerobic cells), cellular response under
hypoxia was strongly cell line dependent with all three pat-
terns of response observed in many cases (Figure 2).
Responses to dasatinib, for example, ranged from hypoxia
resistance in the case of A549 cells (HCR = 0.007) to hypoxia
sensitivity in MDA-MB-231, MDA-MB-468 and MCF7 cells
(HCR = 5.50, 5.23 and 15.00, respectively, Figure 2, Table 2).
Increased sensitivity to dasatinib under hypoxia was with
increased cell kill as opposed to reduced cell growth, with a
significant increase in apoptosis observed in MDA-MB-468,
MDA-MB-231 and MCF7 (Figure 3 and data not shown) cell
lines.
Dasatinib is an orally active inhibitor of Abl and Src
kinases (Lombardo et al., 2004) and in broad agreement with
previous studies (Pham et al., 2009), an increase in total Src
expression was observed under hypoxic conditions in all cell
lines with the exception of H460 cells (Figure 4A). Human
c-Src signalling output is controlled post-translationally by
phosphorylation at Y530 and Y419 (Yeatman, 2004). Phos-
phorylation at Y530 inactivates c-Src whereas full activation
requires phosphorylation at Y419. Under hypoxic conditions,
cell line-dependent changes in the expression of both
pSrcY419 and pSrcY530 occurred (Figure 4A) but no clear
relationship between c-Src and p-Src and hypoxia resistance
or sensitivity exists (Figures 4 and 5). However, the ability of
dasatinib treatment to dephosphorylate pSrcY530 did corre-
late with cellular response and in the hypoxia-sensitive cell
lines, greater dephosphorylation of the inhibitory pSrcY530
occurred (Figures 4B and 5) making cells more sensitive to
dasatinib. In the hypoxia-resistant cell lines, the dephospho-
rylation of pSrcY530 was reduced under hypoxia conditions
(Figures 4B and 5), thereby keeping c-Src in an inactive state.
The ability of dasatinib to dephosphorylate pSrcY530 (rather
than pSrcY419) contributes significantly to the differential
response of cells to dasatinib. Further studies to determine
the effect of dasatinib on Csk and Chk proteins that inacti-
vate Src by phosphorylation at Y530 and the activating Src
activator protein tyrosine phosphatase 1B (PTP1B) (Yeatman,
2004; Roskoski, 2005) are required. Hypoxic sensitization of
cells to dasatinib appears to be independent of HIF1
(Figure 6). This is consistent with other studies showing that
Figure 6
The role of HIF1 in the activity of dasatinib. Western blot analysis of the effect of hypoxia (24 h exposure to 0.1% oxygen) and CoCl2 (6 h exposure
to 150 μM and 24 h exposure to 100 μM CoCl2 under aerobic conditions) on the expression of HIF1α is presented in panel (A). The values
presented below each lane represent the ratio of HIF1α to β-actin expression as determined by densitometry. The response of cells to dasatinib
in the absence and presence of CoCl2 is presented in panel (B). Cells were pretreated with 150 μM CoCl2 for 6 h before a 1 h exposure to dasatinib
and 150 μM CoCl2. Each value presented represents the mean ± SD for three independent experiments. Statistical significance (P < 0.01) between
the control (no CoCl2) and the CoCl2-treated groups is indicated by *.
BJP M Ahmadi et al.
232 British Journal of Pharmacology (2014) 171 224–236
forced expression of HIF1 repressed Src signalling output by
repressing transcription of PTP1B, thereby conferring resist-
ance to dasatinib (Suwaki et al., 2011). As cobalt chloride is
known to stabilize HIF2α in aerobic conditions (Chan et al.,
2002), our results (Figure 6) also suggest that HIF2 is not
involved in the hypoxic sensitization of cells to dasatinib.
Another potential mechanism that may influence response in
normoxia and hypoxia is higher drug efflux capacity in
hypoxic stem cell populations (Challen and Little, 2006).
Further studies are required to verify these and other poten-
tial mechanisms of resistance.
The effect of hypoxia on ErbB receptor (EGFR) signalling
pathways is of current interest (Wouters et al., 2013) and
resistance to gefitinib under hypoxia has been reported in
NSCLC cell lines that harbour both mutant and wild-type
ErbB receptors (Minakata et al., 2012). The results of our study
are broadly in agreement with that resistance to erlotinib,
and gefitinib was observed in some cell lines although HCR
values close to 1 were seen in others (Table 1, Figure 2). The
effect of hypoxia on the expression of ErbB receptors and p-
ErbB receptors varied depending on the cell line (Figure 7A)
with increased expression seen in some cells (e.g. DLD1)
contrasting with no significant change in other cells (e.g.
TK10). Increased expression of ErbB receptors under hypoxia
has been reported previously (Wang and Schneider, 2010;
Misra et al., 2012), but it is not clear why induction is cell line
dependent. A trend between the ability of erlotinib to sup-
press p- ErbB receptors and response under aerobic and
hypoxic conditions exists. In hypoxia-resistant TK10 cells,
reduced dephosphorylation of ErbB receptors was observed
under hypoxic conditions, whereas little difference in the
suppression of p- ErbB receptor expression was observed in
Figure 7
Influence of hypoxia and erlotinib treatment on the expression of ErbB receptors and p-ErbB receptors. The expression of ErbB receptors and p-
ErbB receptors (Y1068) under aerobic conditions and following 24 h exposure to 0.1% oxygen is presented in panel (A). The expression of ErbB
receptors and p- ErbB receptors in TK10 (hypoxia resistant, HCR = 0.09) and DLD-1 cells (hypoxia sensitive, HCR = 1.36) following 24 h exposure
to erlotinib (1–100 μM) under aerobic and hypoxic conditions is presented in panel (B). Graphs show the quantification (±SD) of ErbB receptors
and p- ErbB receptors after normalization to β-actin for a minimum of n = 3 experiments.
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DLD-1 cells where erlotinib was equally active against aerobic
and hypoxic cells (Figure 7B). Our results further support the
view that tumour hypoxia is an important factor that should
be considered when treating patients (Minakata et al., 2012).
Further work is required to identify the mechanisms respon-
sible for the cell-dependent nature of the hypoxia response to
ErbB receptor inhibitors.
Sorafenib inhibits Raf/MEK/ERK signalling (Liu et al.,
2006) but no obvious correlation was observed between
resistance under hypoxia and the expression of proteins
involved in Raf/MEK/ERK signalling (Figure 8). However,
sorafenib is a multi-kinase inhibitor (Matsuda and Fukumoto,
2011) and further studies are required to determine the role of
Raf/MEK/ERK independent pathways in conferring hypoxia
resistance. The resistance of cells under hypoxia is however
potentially significant as sorafenib, by virtue of its anti-
angiogenic properties, has been shown to induce hypoxia in
renal cell carcinoma xenografts (Murakami et al., 2012).
Recent studies have demonstrated that the development of a
resistance to sorafenib is not due to permanent genetic
changes or selection of resistant clones but is due to reversible
changes that occur within the tumour or its microenviron-
ment (Tang et al., 2010; Zhang et al., 2011). It is conceivable
that the induction of hypoxia by sorafenib could generate a
resistance phenotype, an effect that would be transient in
nature depending upon oxygenation levels. Alternative
dosing strategies including low-dose metronomic (Tang et al.,
2010) and high-dose intermittent dosing (Wang et al., 2011)
have shown improved efficacy in preclinical models, but it is
not clear whether this improved efficacy is due to reducing
the induction of tumour hypoxia.
In conclusion, the results of this study demonstrate that
cell lines exposed to normoxic and hypoxic conditions can
induce differential responses to clinically used TKIs. This
includes preferential toxicity towards hypoxic cells as exem-
plified by dasatinib. In the context of the failure to develop
therapies that selectively target hypoxic cells (Semenza,
2012), this study suggests that TKIs that show preferential
toxicity towards hypoxic cells should be evaluated as poten-
tial hypoxia-selective therapies. In the case of dasatinib, the
activity of single-agent dasatinib against solid tumours in the
clinic has so far proved disappointing (Zhang and Yu, 2012),
but further evaluation of dasatinib as a hypoxia-selective drug
could be valuable. In this context, combination strategies
using agents that target the aerobic fraction of tumours
would be required and various preclinical studies have pro-
vided evidence that this is an attractive strategy (Montero
et al., 2011; Raju et al., 2012). While translating the results of
this in vitro study into in vivo efficacy against hypoxic cells is
challenging, this study suggests that certain TKIs should be
re-evaluated as potential hypoxia-selective therapies designed
to overcome hypoxia-induced drug resistance.
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